Clinical trial NCT07010107: A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
Official title: Efficacy and Safety of Anaprazole in the Treatment of Reflux Esophagitis: A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Positive-Controlled Phase III Clinical Trial.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Reflux Esophagitis (RE)
Keywords: Anaprazole
Rabeprazole
Reflux Esophagitis
Lead sponsor: Xuanzhu Biopharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-06-08
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This Phase III clinical trial is designed to assess the efficacy and safety of Anaprazole 60 mg once daily (QD) administered over a period of up to 8 weeks, compared with Rabeprazole 20 mg QD, in patients with reflux esophagitis.


Eligibility criteria: Inclusion Criteria:

1. The patients provided voluntary signed informed consent forms.
2. Aged ≥18 years and ≤75 years old.
3. Endoscopically diagnosed as reflux esophagitis (LA grade B-D) within 14 days before randomization.

Exclusion Criteria:

1. Researchers believe that patients with uncontrolled primary diseases are not suitable for clinical trials, particularly those with a history of severe conditions affecting the cardiovascular, nervous, respiratory, hepatic, renal, or other systems.
2. Patients with concomitant diseases that may affect the esophagus or esophageal motility and, could potentially influence the efficacy evaluation.
3. Patients with a history of prior surgical procedures that could potentially impact esophageal function, or surgeries.
4. Patients confirmed to have active peptic ulcers or active upper/lower gastrointestinal bleeding within the last 30 days via esophagogastroduodenoscopy (EGD).
5. Patients with a history of Zollinger-Ellison syndrome, achalasia of the cardia, secondary esophageal motility disorders, irritable bowel syndrome, inflammatory bowel disease, or other gastrointestinal functional disorders.
6. Patients with a history of malignant tumor or having received treatment for malignant tumor within 5 years prior to randomization.
7. Patients with a history of mental illness or a history of drug or alcohol abuse within 12 months prior to screening.
8. Patients who tested positive for HIV, HBsAg, and/or HCV antibodies during screening.
9. Patients with malignant tumors or a predisposition to malignancy in the stomach or esophagus.
10. Patients with abnormal liver function: AST and/or ALT levels ≥2.0×ULN, and/or total bilirubin (TBIL) levels ≥1.5×ULN.
11. Patients with abnormal renal function: Serum creatinine levels ≥1.5×ULN, blood urea or blood urea nitrogen levels ≥1.5×ULN.
12. Patients with clinically significant ECG abnormalities, including QTc interval prolongation (QTcF ≥450 ms for men and QTcF ≥470 ms for women).
13. Patients with poorly controlled diabetes or hypertension.
14. Patients who were unable to undergo esophagogastroduodenoscopy (EGD).
15. Patients with a known allergy to the components or ingredients of Anaprazole or Rabeprazole.
16. Patients who had used proton pump inhibitors at therapeutic doses within 14 days prior to randomization.
17. Patients who had used therapeutic doses of other drugs for treating acid reflux within 7 days prior to randomization.
18. Patients required to continue receiving non-steroidal anti-inflammatory drugs (NSAIDs), systemic glucocorticoids, or clopidogrel during the trial period.
19. Patients whose assessment may be affected by alcohol, drug, or medication withdrawal during the study.
20. Pregnant or lactating women, as well as patients planning to conceive within 30 days before randomization and up to 6 months following the trial completion.
21. Patients who had participated in other drug clinical trials within 3 months prior to randomization.
22. Patients with other conditions deemed by the researchers as unsuitable for participation in this clinical trial.

Primary outcomes:
measure: The endoscopic healing rate of reflux esophagitis
timeFrame: Up to 8 weeks
Secondary outcomes:
measure: The endoscopic healing rate of reflux esophagitis
timeFrame: Up to 4 weeks
measure: Changes in the severity and frequency of heartburn compared to the baseline
timeFrame: Up to 8 weeks
measure: Changes in the severity and frequency of reflux compared to the baseline
timeFrame: Up to 8 weeks
measure: The rate of improvement in the severity and frequency of heartburn
timeFrame: Up to 8 weeks
measure: The rate of improvement in the severity and frequency of reflux
timeFrame: Up to 8 weeks
measure: Change from baseline in the Gastroesophageal Reflux Disease Health-Related Quality of Life Questionnaire (GERD-HRQL) score
timeFrame: Up to 8 weeks
measure: Adverse events
timeFrame: Up to 8 weeks
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Changhai Hospital
state: Shanghai
Study officials:
References: